Gyre Therapeutics, Inc. Share Price
NASDAQ: GYRE | Small CapGyre Therapeutics, Inc. Stock Performance
Open $6.40 | Prev. Close $6.47 | Circuit Range N/A |
Day Range $6.38 - $6.69 | Year Range $5.46 - $9.36 | Volume 6,012 |
Average Traded $6.47 |
Gyre Therapeutics, Inc. Share Price Today
As of 10 August 2026, Gyre Therapeutics, Inc.'s share price is $6.65. The stock opened at $6.40, compared to its previous close of $6.47. During today's trading session, Gyre Therapeutics, Inc.'s share price traded between $6.38 and $6.69, with an average price of $6.54. Over the past 52 weeks, the stock has recorded a high of $9.36 and a low of $5.46. In terms of performance, Gyre Therapeutics, Inc.'s share price has declined by 19.39% over the last six months and is down 14.03% on a year-on-year basis.
Gyre Therapeutics, Inc. Share Price Chart
Gyre Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $594.14M | PE Ratio (TTM) 110.83 | Dividend Yield N/A |
EPS (TTM) $0.06 | Revenue (TTM) $116.59M | Return On Equity (TTM) 9.32% |
Profit Margin 8.47% | Debt to Equity 0.17 | Quarterly Earnings Growth YoY -34.30% |
Gyre Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Gyre Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $5.93 | $6.65 | +15.55% |
Jul 2026 | $6.52 | $5.75 | -12.54% |
Jun 2026 | $5.92 | $6.58 | +11.62% |
May 2026 | $7.80 | $5.89 | -22.94% |
Apr 2026 | $7.19 | $7.65 | +9.91% |
Mar 2026 | $8.21 | $6.96 | -15.64% |
Feb 2026 | $8.00 | $8.25 | +1.85% |
Jan 2026 | $6.93 | $8.10 | +15.06% |
Dec 2025 | $7.77 | $7.04 | -8.81% |
Nov 2025 | $7.33 | $7.72 | -0.26% |
Oct 2025 | $7.59 | $7.74 | +6.03% |
Sep 2025 | $7.86 | $7.30 | -5.62% |
GYRE Share Price FAQs
What is Gyre Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Gyre Therapeutics, Inc. stock?
What is GYRE's market capitalisation today?
What is GYRE's net income for the last quarter?
What is the 5 year returns of GYRE?
What is the high & low stock price of GYRE today?
Can I buy GYRE shares in India?